News & Views | Telix Pharmaceuticals Limited

Patients Risk Missing Out on Revolution in Cancer Treatment: Report

Tens of thousands of Australians risk missing out on a new era of cancer treatment if Australia fails to fund and build the medical infrastructure needed to support it, according to a landmark new report by Telix.

Investor Webinar: Telix Therapeutics Urology Showcase and Expert Forum

Telix invites investors to join a webinar showcasing the Company’s late-stage and next-generation radiotherapeutic candidates in urologic oncology. In this education session, Telix and global key opinion leaders will provide an overview on the development of its therapeutic candidates in prostate and kidney cancers.

FDA Accepts BLA for TLX250-CDx (Zircaix®) for Kidney Cancer Imaging, Grants Priority Review

Telix today announces that the United States (U.S.) Food and Drug Administration (FDA) has accepted the Biologics License Application (BLA) for its breakthrough investigational kidney cancer PET imaging agent TLX250-CDx (Zircaix®, 89Zr-DFO-girentuximab), granted a Priority Review and provided a PDUFA date of 27 August 2025, paving the way for a U.S. commercial launch in 2025.

Telix Announces Board Renewal

Telix today announces new Director appointments as part of a Board succession planning and renewal process.

Illuccix® Approved in Norway

Telix today announces that its prostate cancer PET imaging agent Illuccix® (kit for the preparation of gallium-68 gozetotide injection) has been granted marketing authorization by NOMA for the detection and localization of prostate-specific membrane antigen (PSMA)-positive lesions in adults with prostate cancer, a broad clinical label.

Telix 2024 Full Year Results: Record Financial Performance and Investment in Future Growth, FY2025 Guidance of up to $1.23 Billion

Telix today announces its financial results for the year ended 31 December 2024.

Illuccix® Approved in the United Kingdom

Telix today announces that the United Kingdom (UK) Medicines and Healthcare Products Regulatory Agency (MHRA) has approved the Marketing Authorization Application (MAA) for its prostate cancer PET imaging agent Illuccix® (kit for the preparation of gallium-68 gozetotide injection).

Telix Completes Acquisition of Next-Generation Therapeutic Assets and Innovative Biologics Technology Platform

Telix today announces it has completed the acquisition from antibody engineering company ImaginAb, Inc. (ImaginAb). The acquisition includes a pipeline of next-generation therapeutic candidates, a proprietary novel biologics technology platform, and a protein engineering and discovery research facility to enhance existing innovation capabilities.

Telix Completes Acquisition of RLS (USA) Inc.

Telix today announces it has completed the acquisition of RLS (USA) Inc. (RLS; RLS Radiopharmacies), America’s only Joint Commission-accredited radiopharmacy network distributing PET, SPECT and therapeutic radiopharmaceuticals.

Illuccix® Receives European Approval

Telix today announces that it has received a positive decision on the Marketing Authorization Application (MAA) for its prostate cancer PET imaging agent Illuccix® (kit for the preparation of gallium-68 gozetotide injection), which was submitted in Europe via a decentralized procedure (DCP).